Latest News
US looks to 2032 as cut-off from Chinese biomanufacturing reliance
US looks to 2032 as cut-off from Chinese biomanufacturing reliance
A revised version of the US BIOSECURE Act will give US biopharma firms until 2032 to sever ties with Chinese suppliers. For WuXi Biologics, this could lead to share buybacks, privatization, or an all-out sale says one analyst.
Deal-Making
ExacellGene has partnered to combine its transposon technology with Cytovance’s manufacturing expertise to develop and produce large molecule biologics.
Sanofi has signed a licensing deal worth up to $1.2 billion with Novavax to commercialize the latter’s adjuvanted COVID-19 vaccine and use the technology to create its own flu shot.
Facilities & Capacity
.jpg?width=700&auto=webp&quality=80&disable=upscale)
Solvias will open a biotech site in Research Triangle Park, North Carolina to enhance its analytical testing services for the cell and gene therapy (CGT) and biologics space.
CDMO Grand River Aseptic Manufacturing (GRAM) is constructing a syringe and cartridge filling center for its biologics pipeline and drug delivery systems.
Global Markets
A revised version of the US BIOSECURE Act will give US biopharma firms until 2032 to sever ties with Chinese suppliers. For WuXi Biologics, this could lead to share buybacks, privatization, or an all-out sale says one analyst.
At the London Biotechnology Show 2024, Microsoft's Thomas Balkizas emphasized AI's burgeoning impact on healthcare, from clinical trials to personalized medicine.
Regulations
A revised version of the US BIOSECURE Act will give US biopharma firms until 2032 to sever ties with Chinese suppliers. For WuXi Biologics, this could lead to share buybacks, privatization, or an all-out sale says one analyst.
The US FDA has approved Beqvez (fidanacogene elaparvovec), Pfizer’s adeno-associated virus (AAV) based gene therapy for the treatment of hemophilia B.
Therapeutic Class
Sanofi has signed a licensing deal worth up to $1.2 billion with Novavax to commercialize the latter’s adjuvanted COVID-19 vaccine and use the technology to create its own flu shot.
Singapore’s SCG Cell Therapy and A*STAR, an official Singapore investor, will team up to build new joint laboratory research labs for cellular immunotherapies.
Upstream & Downstream Processing
Repligen says it is looking at new modalities and its filtration franchise to drive momentum following a mixed first quarter 2024.
Through changing the traditional organizational structure to include all functions in one team, the setup can support complexities in manufacturing projects, says Boehringer Ingelheim.